On October 14 2025, Palisade Bio announced that the Canadian Intellectual Property Office granted patent number 3,174,137, titled “Gut Microbiota Bioactivated PDE4 Inhibitor Precursors,” covering the composition of its lead candidate PALI‑2108.
The patent provides composition‑of‑matter protection for PALI‑2108 until May 28 2041, extending the company’s exclusive rights to the drug’s unique gut‑restricted PDE4 inhibitor design and reinforcing its competitive position in the ulcerative colitis and fibrostenotic Crohn’s disease markets.
The grant strengthens Palisade Bio’s intellectual‑property portfolio and supports the ongoing development of PALI‑2108, positioning the company to advance its clinical program with a robust legal foundation for the drug’s novel mechanism of action.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.